Trials / Completed
CompletedNCT01484119
Efficacy, Safety, and Tolerability Study of ACT-129968 in Patients With Seasonal Allergic Rhinitis
Multi-center, Double-blind, Double-dummy, Randomized, Placebo-controlled, Active-reference, Parallel-group Study to Evaluate the Efficacy, Safety, and Tolerability of ACT-129968 in Adolescent, Adult & Elderly Patients With Seasonal Allergic Rhinitis
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 630 (actual)
- Sponsor
- Idorsia Pharmaceuticals Ltd. · Industry
- Sex
- All
- Age
- 12 Years – 76 Years
- Healthy volunteers
- Not accepted
Summary
This study will assess the efficacy and safety of ACT-129968 in adolescent, adult and elderly patients with seasonal allergic rhinitis, due to mountain cedar pollen.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ACT-129968 | daily tablets |
| DRUG | Placebo | matching placebo tablets and capsules |
| DRUG | Cetirizine | daily capsules |
Timeline
- Start date
- 2011-12-01
- Primary completion
- 2012-02-01
- Completion
- 2012-03-01
- First posted
- 2011-12-02
- Last updated
- 2018-09-28
Locations
7 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01484119. Inclusion in this directory is not an endorsement.